Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
NORCROSS, Ga., Sept. 05, 2017 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Tuesday, September 12 at 11:40 a.m. ET. The conference is being held September 10-12, 2017 at the New York Palace Hotel in New York, NY.
A live webcast of the presentation may be accessed on the Investor Relations section of the Galectin Therapeutics website at www.galectintherapeutics.com. A replay of the webcast will be available after the event.
In addition to the presentation, management will take part in a series of 1x1 and small group meetings. If you would like to attend the conference, or to request a 1x1 meeting, please visit www.rodmanevents.com to register. The Global Investment Conference will feature more than 300 public and private companies from around the world, with over 2,000 attendees anticipated.
About Galectin Therapeutics
Galectin Therapeutics is developing promising therapies for the treatment of fibrotic liver disease, skin diseases, and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
Contacts: Jack Callicutt, Chief Financial Officer (678) 620-3186 [email protected]
